Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Trevi Therapeutics, Inc.

By efain on Fri, 05/14/2021 - 16:05
  • Read more about Trevi Therapeutics, Inc.

An Intermediate Expanded Use Trial of DFMO

  • Read more about An Intermediate Expanded Use Trial of DFMO

vTv Therapeutics Inc.

By efain on Tue, 04/20/2021 - 14:37
  • Read more about vTv Therapeutics Inc.

Reneo Pharmaceuticals Inc.

By efain on Thu, 04/15/2021 - 15:52
  • Read more about Reneo Pharmaceuticals Inc.

Oneness Biotech Company Limited

By efain on Thu, 04/15/2021 - 15:47
  • Read more about Oneness Biotech Company Limited

Oblato, Inc.

By efain on Tue, 04/06/2021 - 17:05
  • Read more about Oblato, Inc.

Pharvaris

By efain on Fri, 03/12/2021 - 13:49
  • Read more about Pharvaris

Exelixis, Inc.

By efain on Fri, 03/05/2021 - 12:53
  • Read more about Exelixis, Inc.

Taiho Oncology, Inc

By efain on Thu, 02/25/2021 - 11:45
  • Read more about Taiho Oncology, Inc

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

  • Read more about 1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 211
  • Page 212
  • Page 213
  • Page 214
  • Current page 215
  • Page 216
  • Page 217
  • Page 218
  • Page 219
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA